publication . Other literature type . Article . 2016

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer

Anthony F. Yu; Martin Fleisher; Sujata Patil; Shawn C. Pun; Clifford A. Hudis; Chau T. Dang; Carlos R. Manrique; Jennifer E. Liu; Richard M. Steingart; Elton Mara; ...
Open Access
  • Published: 16 Mar 2016
  • Publisher: Alphamed Press
Abstract
Introduction. Myocardial strain imaging and blood biomarkers have been proposed as adjuncts to left ventricular ejection fraction (LVEF) monitoring for the early detection of cardiotoxicity during cancer therapy. We report the results of a preplanned cardiac safety analysis of global longitudinal strain (GLS), and troponin-I (TnI) and brain natriuretic peptide (BNP) levels in the phase II study of paclitaxel, trastuzumab, and pertuzumab (THP) for metastatic HER2-positive breast cancer. Patients and Methods. Patients with 0–1 lines of prior therapy were treated with weekly paclitaxel (80 mg/m2) plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and pertu...
Subjects
Medical Subject Headings: cardiovascular systemskin and connective tissue diseasesmusculoskeletal system
free text keywords: 3, Breast Cancer, Cardiotoxicity, Heart failure, Trastuzumab, Pertuzumab, Imaging, Biomarkers, Cancer Research, Oncology, medicine.medical_specialty, medicine, Internal medicine, medicine.disease, Metastatic breast cancer, Urology, medicine.drug, Ejection fraction, Loading dose, business.industry, business
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
36 references, page 1 of 3

Slamon, DJ, Leyland-Jones, B, Shak, S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792 [OpenAIRE] [PubMed]

Perez, EA, Romond, EH, Suman, VJ. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32: 3744-3752 [OpenAIRE] [PubMed]

Slamon, D, Eiermann, W, Robert, N. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365: 1273-1283 [OpenAIRE] [PubMed]

Romond, EH, Jeong, JH, Rastogi, P. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012; 30: 3792-3799 [OpenAIRE] [PubMed]

Cote, GM, Sawyer, DB, Chabner, BA. ERBB2 inhibition and heart failure. N Engl J Med. 2012; 367: 2150-2153 [OpenAIRE] [PubMed]

Scheuer, W, Friess, T, Burtscher, H. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009; 69: 9330-9336 [OpenAIRE] [PubMed]

Phillips, GD, Fields, CT, Li, G. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014; 20: 456-468 [PubMed]

Ahn, ER, Vogel, CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2012; 131: 371-383 [PubMed]

Agus, DB, Gordon, MS, Taylor, C. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005; 23: 2534-2543 [PubMed]

Swain, SM, Baselga, J, Kim, SB. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372: 724-734 [OpenAIRE] [PubMed]

Swain, SM, Ewer, MS, Cortés, J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study. The Oncologist . 2013; 18: 257-264 [OpenAIRE] [PubMed]

Plana, JC, Galderisi, M, Barac, A. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27: 911-939 [PubMed]

Thavendiranathan, P, Grant, AD, Negishi, T. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013; 61: 77-84 [PubMed]

Otterstad, JE, Froeland, G, St John Sutton, M. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997; 18: 507-513 [OpenAIRE] [PubMed]

Thavendiranathan, P, Poulin, F, Lim, KD. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J Am Coll Cardiol. 2014; 63 (25 pt A): 2751-2768 [PubMed]

36 references, page 1 of 3
Abstract
Introduction. Myocardial strain imaging and blood biomarkers have been proposed as adjuncts to left ventricular ejection fraction (LVEF) monitoring for the early detection of cardiotoxicity during cancer therapy. We report the results of a preplanned cardiac safety analysis of global longitudinal strain (GLS), and troponin-I (TnI) and brain natriuretic peptide (BNP) levels in the phase II study of paclitaxel, trastuzumab, and pertuzumab (THP) for metastatic HER2-positive breast cancer. Patients and Methods. Patients with 0–1 lines of prior therapy were treated with weekly paclitaxel (80 mg/m2) plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and pertu...
Subjects
Medical Subject Headings: cardiovascular systemskin and connective tissue diseasesmusculoskeletal system
free text keywords: 3, Breast Cancer, Cardiotoxicity, Heart failure, Trastuzumab, Pertuzumab, Imaging, Biomarkers, Cancer Research, Oncology, medicine.medical_specialty, medicine, Internal medicine, medicine.disease, Metastatic breast cancer, Urology, medicine.drug, Ejection fraction, Loading dose, business.industry, business
Related Organizations
Funded by
NIH| MOUSE GENETICS
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
36 references, page 1 of 3

Slamon, DJ, Leyland-Jones, B, Shak, S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792 [OpenAIRE] [PubMed]

Perez, EA, Romond, EH, Suman, VJ. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014; 32: 3744-3752 [OpenAIRE] [PubMed]

Slamon, D, Eiermann, W, Robert, N. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365: 1273-1283 [OpenAIRE] [PubMed]

Romond, EH, Jeong, JH, Rastogi, P. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012; 30: 3792-3799 [OpenAIRE] [PubMed]

Cote, GM, Sawyer, DB, Chabner, BA. ERBB2 inhibition and heart failure. N Engl J Med. 2012; 367: 2150-2153 [OpenAIRE] [PubMed]

Scheuer, W, Friess, T, Burtscher, H. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009; 69: 9330-9336 [OpenAIRE] [PubMed]

Phillips, GD, Fields, CT, Li, G. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014; 20: 456-468 [PubMed]

Ahn, ER, Vogel, CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2012; 131: 371-383 [PubMed]

Agus, DB, Gordon, MS, Taylor, C. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005; 23: 2534-2543 [PubMed]

Swain, SM, Baselga, J, Kim, SB. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372: 724-734 [OpenAIRE] [PubMed]

Swain, SM, Ewer, MS, Cortés, J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study. The Oncologist . 2013; 18: 257-264 [OpenAIRE] [PubMed]

Plana, JC, Galderisi, M, Barac, A. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27: 911-939 [PubMed]

Thavendiranathan, P, Grant, AD, Negishi, T. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013; 61: 77-84 [PubMed]

Otterstad, JE, Froeland, G, St John Sutton, M. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997; 18: 507-513 [OpenAIRE] [PubMed]

Thavendiranathan, P, Poulin, F, Lim, KD. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J Am Coll Cardiol. 2014; 63 (25 pt A): 2751-2768 [PubMed]

36 references, page 1 of 3
Any information missing or wrong?Report an Issue